Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-2 of 2
Keywords: Advanced renal cell carcinoma
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma
Available to PurchaseSubject Area:
Further Areas
Hiroki Ishihara, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Toshio Takagi, Junpei Iizuka, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
Journal:
Urologia Internationalis
Urol Int (2022) 106 (4): 368–375.
Published Online: 07 April 2022
... carcinoma Advanced renal cell carcinoma Targeted therapy Prognosis Antitumor drugs are approved based on the data from clinical trials in cancer. In metastatic renal cell carcinoma (mRCC), previous trials demonstrated efficacy and safety of molecular-targeted therapy, including tyrosine kinase...
Journal Articles
Cyclic Interf eron Alpha Treatment in Metastatic Renal Cell Carcinoma: Results of a Phase II Study and Review of the Literature
Available to PurchaseSubject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (1997) 58 (1): 8–12.
Published Online: 04 February 2010
... responses or stable disease showed a long-lasting stabilization ( > 12 months) of the disease with a good quality of life. In summary, in advanced renal cell carcinoma patients, the objective response rate of a cyclic treatment with IFN-α is rather low. However, a long-lasting stabilization...
